NVS Novartis AG
XNYS
150.98
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
NVS
$150.98
—
Key stats
$150.98
- 52-Week Range
- $121.57 – $170.46
- YTD
- +8.98%
- IV Rank (30D)
- 44.08
- Straddle Price
- $9.40
- P/C Vol Ratio
- 8.78
- Market Cap
- $297.0B
- Open
- $156.08
- Day Range
- $149.17 – $156.08
- Volume
- 4,358,807
- Prev Close
- $156.27
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.12% |
| Beta vs SPY | 0.61 |
| Cost of Equity (CAPM) | 8.17% (VRP-adj) |
| WACC | 8.21% |
| Volatility Risk Premium | +38.7pp (IV − HV30) |
| Effective Tax Rate | 13.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $9.7B |
| Return on Equity (TTM) | 9.3% |
| Book / Price | 12.4% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| Market-Implied Growth | +20.5% (reverse-DCF on current price) |
| SMA 50 | $148.12 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $146.13 |
| Bollinger Width / SMA20 | 8.8% (drives anchor stability) |
| Net Debt | $-11.4B |
| Market Cap | $377B |
Peers used for multiples: ABBV, AMGN, BMY, GSK, JNJ, LLY, MRK, PFE
60-Day Conviction
17%
20-Day Fair Value
≈ by Nov 23, 2026
$151.98
α +0.6%
rank 12%
conviction
37%
40-Day Fair Value
≈ by Dec 22, 2026
$154.44
α +2.2%
rank 20%
conviction
68%
60-Day Fair Value
≈ by Jan 20, 2027
$151.77
α +0.4%
rank 18%
conviction
17%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $78.47 | 0% | |
| DDM (Gordon) | $94.51 | 20% | |
| Peer P/E | n/a | 0% | median 39.3× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.2× · 7 peers |
| Peer P/B | $158.80 | 7% | median 8.2× · 6 peers |
| Peer P/S | n/a | 0% | median 6.2× · 7 peers |
| Market Anchor (SMA50) | $148.12 | 49% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $156.89 | 24% | 29 strikes · skew +0.26 |
As of 2026-10-23 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNYS
- Market Cap
- $297.0B
- Employees
- 75,267
- List Date
- 1996-11-07
- CIK
- 0001114448
- Next Earnings
- 2026-10-27 (Pre-Market)
- EPS Forecast
- $2.25 (5 est.)
- Homepage
- https://www.novartis.com
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -4.13% | -1.09% | -1.72% | 2.45% | 7.80% | 7.32% | 1.77% |
| Feb | -4.29% | -0.82% | -4.66% | -4.14% | 3.38% | 11.64% | 0.19% |
| Mar | -2.25% | 0.72% | 9.76% | -5.22% | 0.78% | -8.46% | -0.78% |
| Apr | -0.98% | 0.39% | 10.86% | 1.31% | 3.54% | -4.66% | 1.74% |
| May | 2.30% | 3.75% | -6.13% | 5.77% | 3.98% | 2.46% | 2.02% |
| Jun | 3.54% | -5.70% | 3.91% | 3.60% | 3.69% | 7.58% | 2.77% |
| Jul | 0.81% | 1.74% | 6.21% | 4.64% | -7.60% | 1.19% | 1.17% |
| Aug | 0.13% | -5.97% | -2.75% | 7.84% | 9.76% | -1.05% | 1.33% |
| Sep | -11.73% | -5.38% | 1.13% | -2.94% | 1.26% | -11.58% | -4.87% |
| Oct | 0.91% | 5.82% | -7.84% | -5.37% | -6.02% | 7.14%* | -0.89% |
| Nov | -5.18% | 10.49% | 3.86% | -3.27% | 5.28% | -- | 2.24% |
| Dec | 9.58% | 1.00% | 2.89% | -7.15% | 6.90% | -- | 2.64% |
| Total | -12.12% | 3.73% | 14.40% | -3.81% | 36.19% | 9.33% | 7.95% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $146.42
SMA 50: $148.11
SMA 200: $151.43
Current: $151.12
EMA 12: $149.82
EMA 26: $147.78
MACD: 2.0406 | Signal: 1.2955
BULLISH
ADX (14): 19.05
RANGE
+DI: 36.32
−DI: 28.00
Momentum Oscillators
RSI (14): 56.88
NEUTRAL
Stoch %K: 86.58
Stoch %D: 93.22
Williams %R: -34.30
Volume & Volatility
BB Upper: $156.03
BB Lower: $136.81
NEUTRAL
OBV: 25,914,744
Vol SMA 20: 1,912,208
Vol ROC: 129.28%
ATR: $2.97
True Range: $7.10
HV 20: 24.4%
HV 30: 20.9%
HV 60: 39.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-25T00:00:00 – 2026-10-23T00:00:00
AI Analysis
LLM Stock Analysis Report: NVS
Executive Summary:
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers: Neutral market sentiment, low volatility, and positive news headlines.
Primary Risks: Lack of earnings data, options activity suggesting bearish sentiment.
Investment Thesis: Novartis' steady performance in a rapidly evolving pharmaceutical landscape, combined with its strong fundamentals, makes it an attractive investment opportunity. However, the lack of recent earnings data and bearish options market sentiment temper our enthusiasm.
Recent News Sentiment Impact: Positive news headlines (65% positive) from recent collaborations and licensing deals, as well as the FDA approval for Fabhalta, have contributed to the neutral market sentiment.
Technical Analysis:
Trend Direction: Short-term: RANGE-bound (1-4 weeks), Medium-term: UPTREND (1-3 months), Long-term: UPTREND (3-12 months)
Support/Resistance Levels: Key price levels from moving averages and technical patterns: + SMA 20: $154.56 + SMA 50: $152.90 + Upper Bollinger Band: $159.88
Momentum Signals: + RSI (14): 54.77 (neutral) + MACD: Bullish crossover above signal line + Stochastic %K: 52.80 + Williams %R: -39.89
Volume Analysis: Volume trends and institutional interest signals: + Volume SMA 20: 1661466.40 + On-Balance Volume (OBV): 39156042.11 + Volume Rate of Change: -45.51%
News & Sentiment Analysis:
Recent Headlines Summary: Neutral market sentiment, with a mix of positive and neutral news headlines.
Sentiment Assessment: Aggregate news sentiment: NEUTRAL
Catalyst Identification: Upcoming FDA approvals, product launches, and licensing deals may drive the stock's performance.
Market Narrative: News headlines align generally with the neutral technical signals, but the lack of recent earnings data creates uncertainty.
Risk & Volatility Assessment:
Beta Interpretation: Low risk relative to market (beta <0.8)
Volatility Regime: Current volatility is low compared to historical levels.
Options Market Signals: IV Rank: 19.5% (Low), Put/Call Volume Ratio: 2.32 (Bearish sentiment)
Downside Protection: Support levels and risk management considerations: + SMA 20: $154.56 + SMA 50: $152.90
Market Context & Positioning:
Sector Performance: Novartis' performance is in line with the broader pharmaceutical sector.
Institutional Activity: Volume patterns suggesting institutional interest, but options market sentiment is bearish.
Correlation Analysis: The stock moves relatively less than the market (R-squared interpretation).
Relative Valuation: Position within trading range:
Key Levels & Action Items:
Critical Price Levels: + SMA 20: $154.56 + Upper Bollinger Band: $159.88
Breakout/Breakdown Levels: Technical levels that could trigger significant moves: + SMA 50: $152.90
Time-Sensitive Catalysts: Upcoming FDA approvals, product launches, and licensing deals.
Risk Management: Stop-loss levels and position sizing considerations: + SMA 20: $154.56 + Lower Bollinger Band: $149.25
Generated
News
All NVS news →
Showing 1–10 of 18
Page 1 of 2
NVS Options Activity & IV Rank
NVS IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 27.9%
7-DTE IV: —
Expected Move: $9.40
7-DTE Move: $9.40
Days to Exp: 28 (2026-11-20)
Options Flow
Call Volume: 455
Put Volume: 3,993
P/C Volume: 8.776
BEARISH
Call OI: 7,671
Put OI: 21,937
P/C OI: 2.86
Total OI: 29,608
ATM Options Pricing
ATM Call: $5.50
ATM Put: $3.90
Call %: 3.6%
Put %: 2.6%
Chain Summary
Chain Volume: 11,061
Chain OI: 109,454
Last Updated: 10/23/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 1st percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
1%
vs own history
GEX tilt
-0.52
OI-weighted, today
Vanna tilt
+0.19
δ-sensitivity to IV
Charm tilt
-0.22
δ-decay vs time
? What is this?
· 51 ATM contracts, 67k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
25%
+2.5
pts
EXTREME
ATM 28.0% / Wing 30.5%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)44.1MediumOct 23
Straddle Price (30 DTE)$9.40Oct 23
Beta Analysis
Risk Metrics
Beta: 0.3121
Alpha: 13.50%
Correlation: 0.1466
R-Squared: 2.1%
Stock Volatility: 27.1%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own NVS
6 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $123.5M | #118 of 3138 | -29.1% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $118.8M | #290 of 3716 | new | 13F | |
| Citadel Hedge fund Ken Griffin | $50.3M | #685 of 6285 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $19.4M | #495 of 4729 | +4.6% | 13F | |
| Point72 Hedge fund Steve Cohen | $16.6M | #630 of 1945 | -62.6% | 13F | |
| Glenview Capital Hedge fund Larry Robbins | $13.6M | #37 of 42 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
NVS Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 2,409,592,249 (as of 2016-12-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
27 filers$1.18B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $298.46M | 25.30% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $227.89M | 19.32% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $204.14M | 17.30% | 2026-06-30 |
| 4 | LMR Partners LLP | $141.61M | 12.00% | 2026-06-30 |
| 5 | Walleye Capital LLC | $76.64M | 6.50% | 2026-06-30 |
| 6 | Optiver Holding B.V. | $47.82M | 4.05% | 2026-06-30 |
| 7 | PEAK6 LLC | $29.57M | 2.51% | 2026-06-30 |
| 8 | Point72 Asset Management, L.P. | $25.39M | 2.15% | 2026-06-30 |
| 9 | DIADEMA PARTNERS LP | $23.51M | 1.99% | 2026-06-30 |
| 10 | D. E. Shaw & Co., Inc. Custodian | $19.75M | 1.67% | 2026-06-30 |
| 11 | TUDOR INVESTMENT CORP ET AL | $11.10M | 0.94% | 2026-06-30 |
| 12 | Squarepoint Ops LLC | $10.30M | 0.87% | 2026-06-30 |
| 13 | Millennium Management LLC Custodian | $9.97M | 0.84% | 2026-06-30 |
| 14 | Wolverine Trading, LLC Custodian | $9.34M | 0.79% | 2025-09-30 |
| 15 | IMC-Chicago, LLC Custodian | $9.09M | 0.77% | 2026-06-30 |
| 16 | CAPITAL FUND MANAGEMENT S.A. | $6.96M | 0.59% | 2026-06-30 |
| 17 | Walleye Trading LLC | $6.68M | 0.57% | 2026-06-30 |
| 18 | Simplex Trading, LLC Custodian | $5.88M | 0.50% | 2026-06-30 |
| 19 | Verition Fund Management LLC | $4.70M | 0.40% | 2026-06-30 |
| 20 | DLD Asset Management, LP | $4.70M | 0.40% | 2026-06-30 |
| 21 | Balyasny Asset Management L.P. | $3.67M | 0.31% | 2026-06-30 |
| 22 | GROUP ONE TRADING LLC Custodian | $1.14M | 0.10% | 2026-06-30 |
| 23 | Two Sigma Investments, LP Custodian | $611.21K | 0.05% | 2026-06-30 |
| 24 | Limestone Investment Advisors LP | $423.14K | 0.04% | 2026-06-30 |
| 25 | Persistent Asset Partners Ltd | $288.05K | 0.02% | 2026-06-30 |
29 filers$2.30B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | LMR Partners LLP | $1.00B | 43.68% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $361.46M | 15.75% | 2026-06-30 |
| 3 | Caption Management, LLC | $157.50M | 6.86% | 2026-06-30 |
| 4 | Optiver Holding B.V. | $120.41M | 5.25% | 2026-06-30 |
| 5 | Citadel Advisors LLC Custodian | $107.57M | 4.69% | 2026-06-30 |
| 6 | Jane Street Group, LLC Custodian | $86.65M | 3.77% | 2026-06-30 |
| 7 | Walleye Capital LLC | $79.74M | 3.47% | 2026-06-30 |
| 8 | Point72 Asset Management, L.P. | $74.47M | 3.24% | 2026-06-30 |
| 9 | Citigroup Inc. Custodian | $71.93M | 3.13% | 2026-06-30 |
| 10 | DIADEMA PARTNERS LP | $47.02M | 2.05% | 2026-06-30 |
| 11 | Barclays PLC Custodian | $44.34M | 1.93% | 2026-06-30 |
| 12 | CAPITAL FUND MANAGEMENT S.A. | $27.79M | 1.21% | 2026-06-30 |
| 13 | GROUP ONE TRADING LLC Custodian | $19.97M | 0.87% | 2026-06-30 |
| 14 | IMC-Chicago, LLC Custodian | $16.33M | 0.71% | 2026-06-30 |
| 15 | TUDOR INVESTMENT CORP ET AL | $12.18M | 0.53% | 2026-06-30 |
| 16 | Millennium Management LLC Custodian | $10.06M | 0.44% | 2026-06-30 |
| 17 | Wolverine Trading, LLC Custodian | $8.71M | 0.38% | 2025-09-30 |
| 18 | Simplex Trading, LLC Custodian | $8.45M | 0.37% | 2026-06-30 |
| 19 | DLD Asset Management, LP | $8.23M | 0.36% | 2026-06-30 |
| 20 | Squarepoint Ops LLC | $6.54M | 0.28% | 2026-06-30 |
| 21 | SIG BROKERAGE, LP | $5.88M | 0.26% | 2026-06-30 |
| 22 | Parallax Volatility Advisers, L.P. | $5.88M | 0.26% | 2026-06-30 |
| 23 | D. E. Shaw & Co., Inc. Custodian | $4.09M | 0.18% | 2026-06-30 |
| 24 | Cohen Capital Management, Inc. | $3.25M | 0.14% | 2026-09-30 |
| 25 | Balyasny Asset Management L.P. | $2.44M | 0.11% | 2026-06-30 |
ETF Holders
50 ETFs hold NVS
25 shown · $984.14M total exposure · 0.68% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | DFIV Dimensional International Value ETF | Dimensional | 0.62% | $136.8M | $21.8B | 2026-10-21 |
| 2 | DFAI Dimensional International Core Equity Market ETF | Dimensional | 0.67% | $121.1M | $18.0B | 2026-10-21 |
| 3 | DFIC Dimensional International Core Equity 2 ETF | Dimensional | 0.73% | $111.4M | $15.2B | 2026-10-21 |
| 4 | AVDE Avantis International Equity ETF | Avantis | 0.47% | $93.0M | $19.6B | 2026-10-21 |
| 5 | DIHP Dimensional International High Profitability ETF | Dimensional | 1.38% | $90.5M | $6.5B | 2026-10-21 |
| 6 | DFAX Dimensional World ex US Core Equity 2 ETF | Dimensional | 0.65% | $79.7M | $12.1B | 2026-10-21 |
| 7 | FENI Fidelity Enhanced International ETF | Fidelity | 0.47% | $54.4M | $11.6B | 2026-10-21 |
| 8 | PPH VanEck Pharmaceutical ETF | VanEck | 3.69% | $39.4M | $1.1B | 2026-10-21 |
| 9 | FVD First Trust Value Line® Dividend Index Fund | First Trust | 0.44% | $35.0M | $7.9B | 2026-10-21 |
| 10 | LCAP Principal Capital Appreciation Select ETF | Nport | 1.49% | $27.2M | — | 2026-06-30 |
| 11 | IDVO Amplify CWP International Enhanced Dividend Income ETF | Amplify | 1.53% | $21.2M | $1.4B | 2026-10-22 |
| 12 | PXF Invesco RAFI Developed Markets ex-U.S. ETF | Nport | 0.70% | $19.5M | — | 2026-04-30 |
| 13 | GQGU GQG US Equity ETF | Nport | 3.40% | $19.1M | — | 2026-06-30 |
| 14 | NUDM Nuveen ESG International Developed Markets Equity ETF | Nport | 2.47% | $17.5M | — | 2026-07-31 |
| 15 | FTHI First Trust BuyWrite Income ETF | First Trust | 0.67% | $17.4M | $2.6B | 2026-10-21 |
| 16 | BFLX iShares Flexible Equity Active ETF | iShares (BlackRock) | 0.75% | $16.7M | $2.2B | 2026-10-21 |
| 17 | PID Invesco International Dividend Achievers ETF | Invesco | 1.81% | $16.0M | — | 2026-10-21 |
| 18 | DFSI Dimensional International Sustainability Core 1 ETF | Dimensional | 1.02% | $12.1M | $1.2B | 2026-10-21 |
| 19 | QLTI GMO International Quality ETF | Nport | 4.01% | $11.4M | — | 2026-05-31 |
| 20 | AQEC AQE Core ETF | Nport | 1.82% | $10.4M | — | 2026-06-30 |
| 21 | APIE ActivePassive International Equity ETF | Nport | 0.88% | $9.2M | — | 2026-05-31 |
| 22 | GMOI GMO International Value ETF | Nport | 1.53% | $7.0M | — | 2026-05-31 |
| 23 | KAT Scharf ETF | Nport | 1.06% | $6.9M | — | 2026-06-30 |
| 24 | YOKE YOKE Core ETF | Nport | 2.76% | $6.4M | — | 2026-07-31 |
| 25 | BINV Brandes International ETF | Nport | 0.98% | $4.8M | — | 2026-06-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q4 '25 | 2025-12-31 | — | — | — | — |
| Q4 '24 | 2024-12-31 | — | — | — | — |
| Q4 '23 | 2023-12-31 | — | — | — | — |
| Q4 '22 | 2022-12-31 | — | — | — | — |
| Q4 '21 | 2021-12-31 | — | — | — | — |
| Q4 '20 | 2020-12-31 | — | — | — | — |
| Q4 '19 | 2019-12-31 | — | — | — | — |
| Q4 '18 | 2018-12-31 | — | — | — | — |
| Q4 '17 | 2017-12-31 | — | — | — | — |
| Q4 '16 | 2016-12-31 | — | — | — | — |
| Q2 '16 | 2016-06-30 | $12.68B | $1.80B | $0.75 | $3.11B |
| Q1 '16 | 2016-03-31 | $11.81B | $2.01B | $0.84 | $1.54B |
Q4 2025 • period ending 2025-12-31 • filed 2026-02-04
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
74.08
P/B
4.86
P/S
9.76
EV/EBITDA
42.34
EV/Sales
10.04
ROE
6.5%
ROA
3.7%
Div Yield
2.18%
FCF Yield
2.47%
Debt/Equity
0.24
Current Ratio
—
Market Cap
$364.14B
as of 2026-10-23
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
5.62M
SI % of Float
0.28%
Days to Cover
2.93
Short Vol Ratio
46.5%
Free Float
—
Float %
—
Short interest 2026-09-30 • Short volume 2026-10-23